Table I.
Clinicopathological characteristics of patients with breast cancer enrolled in the present study.
| Case number | Sex | Age, years | Mutation | ER | PR | HER2 | Ki67/MIB1 | Molecular subtype predicted | Surgical resection, year | Hospital institutea |
|---|---|---|---|---|---|---|---|---|---|---|
| Case 01 | Female | 41 | BRCA 2 458stop | – | – | – | – | – | 1997 | SC-BS |
| Case 02 | Female | 46 | BRCA X | – | – | – | – | – | 1997 | SC-BS |
| Case 03 | Female | 42 | BRCA 2 T703N | Positive | Positive | Negative | Negative | Luminal A | 2005 | FP-BS |
| Case 04 | Female | 43 | BRCA 1 C64R | Negative | Negative | Negative | Positive | Triple-negative | 2011 | FP-BS |
| Case 05 | Female | 49 | BRCA X | Positive | Positive | – | Negative | Luminal A | 2005 | SC-BS |
| Case 06 | Female | 38 | BRCA 1 C64R | Negative | Negative | Negative | Positive | Triple-negative | 2008 | SA-BS |
| Case 07 | Female | 33 | BRCA 2 Q2960X | Positive | Positive | Positive | Positive | Luminal B | 2011 | FP-BS |
| Case 08 | Female | 51 | BRCA X | Positive | Positive | Negative | Negative | Luminal A | 2005 | SA-BS |
| Case 09 | Female | 60 | BRCA X | Positive | Positive | – | – | Luminal A | 2007 | SA-BS |
| Case 10 | Female | 59 | BRCA X | Positive | Positive | Positive | Negative | Luminal B | 2008 | SA-BS |
| Case 11 | Female | 36 | BRCA 1C64R | Negative | Negative | Negative | Positive | Triple-negative | 2009 | FP-BS |
| Case 12 | Female | 50 | BRCA X | Positive | Positive | Negative | Negative | Luminal A | 2008 | FP-BS |
| Case 13 | Female | 38 | BRCA1 M1652I | Negative | Negative | Negative | Positive | Triple-negative | 2001 | SC-BS |
| Case 14 | Female | 43 | BRCA X | Positive | Positive | Negative | Positive | Luminal A | 2007 | SC-BS |
| Case 15 | Female | 41 | BRCA X | Positive | Positive | Positive | Negative | Luminal B | 2000 | SC-BS |
| Case 16 | Female | 43 | BRCA X | Positive | Positive | Negative | Negative | Luminal A | 2006 | SC-BS |
| Case 17 | Female | 43 | BRCA X | Positive | Positive | Negative | Positive | Luminal A | 2002 | SC-BS |
| Case 18 | Male | 49 | BRCA 2 delA9158FS + 29 stop | Positive | Negative | Positive | Negative | HER2-enriched | 2007 | SC-BS |
| Case 19 | Male | 45 | BRCA X | Positive | Negative | Negative | Positive | Luminal A | 2011 | FP-BS |
| Case 20 | Male | 46 | BRCA X | Positive | Positive | Positive | Positive | Luminal B | 2012 | FP-BS |
| Case 21 | Male | 79 | BRCA X | – | – | – | – | – | 2007 | CR |
| Case 22 | Male | 71 | BRCA X | – | – | – | – | – | 2009 | CR |
| Case 23 | Male | 54 | BRCA X | Negative | Negative | Positive | Negative | HER2-enriched | 2011 | CR |
| Case 24 | Male | 48 | BRCA X | Positive | Positive | Negative | Positive | Luminal A | 2012 | PC |
a
SC-BS, Spedali Civili of Brescia, Brescia, Italy; FP-BS, Fondazione Poliambulanza, Brescia, Italy; SA-BS, Istituto Clinico Sant'Anna, Brescia, Italy; CR, ASST of Cremona, Hospital of Cremona, Cremona, Italy; PC, Guglielmo da Saliceto Hospital, Piacenza, Italy. -, information not available in the histopathological report; ER, estrogen receptor; MIB1, MIB E3 ubiquitin protein ligase 1; PR, progesterone receptor.